



Christian M. Pangratz

25+

YEARS IN LIFE SCIENCES

US\$1.5B

LARGEST DEAL LED

€32M+

EQUITY RAISED

Multiple

CEO MANDATES

Biography

Christian Pangratz is an international life-sciences executive with more than 25 years of leadership experience across biotechnology, specialty pharma and platform-based businesses in Europe, North America and Asia. He has held multiple CEO and senior executive roles in venture-backed and publicly listed companies spanning discovery, preclinical and clinical-stage development, and is known as a builder and operator who closes transactions — translating science into partnerships, financings and exits.

His career combines deep business-development and out-licensing expertise with hands-on general management. He has led landmark transactions including a US\$1.5 billion partnership with AstraZeneca (the largest in Nektar Therapeutics' history) and the €130 million trade sale of Activaero to Vectura and has raised over €32 million in equity together with substantial non-dilutive funding. Across CEO mandates he has reset strategy and operating models, secured financing at critical inflection points, strengthened governance and reporting, and built cross-functional teams spanning R&D, CMC, finance, business development and operations.

Science-literate and platform-experienced, he is equally comfortable in board-, investor- and partner-facing settings and in the PE-backed and listed-company environments. He is based near Munich, Germany.

Signature Achievements

US\$1.5B Led the AstraZeneca partnership at Nektar Therapeutics — US\$125M upfront, US\$1.5B total value; the largest deal in the company's history (at that time).

€130M Co-led and orchestrated the trade sale of Activaero to Vectura, delivering a successful exit for shareholders.

€25.5M At Sterna Biologicals, secured €3.5M bridge financing and a €22M Series A, completed three Phase 2a studies and built the executive team.

7 deals At Secarna Pharmaceuticals, closed seven revenue-generating partnerships in three years and drove the company to cash-flow neutrality.

€5.7M At Orikin Bio, structured and closed a pre-Series A financing within 12 months, recruited a new CSO/CDO and established stronger board and reporting cadence.

Fit for the Mandate

Converting a science-led platform into a partnering or trade-sale outcome:

- **A partnering / transaction outcome** — a career built on out-licensing and trade sales, from first outreach to signed deal, including a US\$1.5B partnership and a €130M exit.

- **A science-led diagnostics platform** — science-literate leadership, translating complex science into a commercial and partner story.
- **A WSE-listed, investor-facing company** — experience in listed and PE-backed settings, and credibility in board-, investor- and partner-facing environments.
- **Value realized internationally** — a network and deal record spanning Europe, North America and Asia — where future partners and acquirers sit.

Selected Professional Experience

Years	Company	Role
2024–2026	ORIKINE BIO	Chief Executive Officer — therapeutic cytokine platform (Barcelona)
2023–2024	ATRIVA THERAPEUTICS	Chief Executive Officer — antiviral small molecules (Munich)
2018–2022	STERNA BIOLOGICALS	Chief Executive Officer — clinical-stage antisense oligonucleotides (Munich)
2018–2022	SECARNA PHARMACEUTICALS	Managing Director — antisense oligonucleotide platform (Munich)
2016–2017	VECTURA	SVP, Business Development — respiratory delivery (London)
2014–2016	SKYEPHARMA	EVP, Business Development, Alliance & Program Management (London/Basel)
2011–2014	ACTIVAERO	Chief Business Officer — drug-device combination products (Munich)
2004–2011	NEKTAR THERAPEUTICS	Executive Director, Business Development (San Francisco)

Education & Languages

- **Education** — Executive education at Stanford University, UC Berkeley and INSEAD. M.A. in International Business and B.A. in Business Administration (Departmental Honors), Webster University, Vienna.
- **Languages** — Fluent in German and English; basic French and Spanish